Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jul 31, 2013

Filed with the SEC on Sep 16, 2013 and accepted by EDGAR at Sep 13, 2013, 18:33 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-07-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-05-01 to 2013-07-31$0us-gaap:Revenues
Gross profit3 months2013-05-01 to 2013-07-31$0us-gaap:GrossProfit
Operating income3 months2013-05-01 to 2013-07-31−$1.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2013-05-01 to 2013-07-31$10.4kus-gaap:InterestExpense
Net income3 months2013-05-01 to 2013-07-31−$4.7mus-gaap:NetIncomeLoss
Basic EPS3 months2013-05-01 to 2013-07-31−$0.01us-gaap:EarningsPerShareBasic
Operating cash flow3 months2013-05-01 to 2013-07-31−$159.7kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2013-07-31$206.0kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-07-31$1.8mus-gaap:AssetsCurrent
Total assetsAt period end2013-07-31$3.4mus-gaap:Assets
Current liabilitiesAt period end2013-07-31$994.2kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-07-31$994.2kus-gaap:Liabilities
Shareholders' equityAt period end2013-07-31$1.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001157075-13-000015. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.